Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis

Table 3 Adjusted logistic regression for associations between immunosuppression type and severe acute respiratory syndrome coronavirus 2 infection: Sensitivity analysis for sub-population with full model for end stage liver disease 3.0 score

Immunosuppressant	Odds ratio	P value	95%CI
Prednisone	0.93	0.74	0.58-1.43
Azathioprine	1.07	0.79	0.63-1.74
Budesonide	0.60	0.36	0.18-1.57
Tacrolimus	0.76	0.57	0.25-1.81
Mycophenolate mofetil	1.56	0.68	0.08-8.97
Cyclosporine	0.93	0.89	0.27-2.38
Azathioprine × budesonide	4.44	0.02	1.29-16.72
Prednisone × azathioprine	0.93	0.86	0.41-2.10
Prednisone × budesonide	1.46	0.56	0.39-5.16
Budesonide × mycophenolate mofetil	1.92e-06	0.99	NA, infinity
Prednisone × mycophenolate mofetil	0.29	0.41	0.01-8.19
Budesonide × tacrolimus	3.21	0.23	0.38-20.00
Prednisone × tacrolimus	1.85	0.32	0.58-6.69

NA: Not available.